Long-term effectiveness of fremanezumab in episodic and chronic migraine patients in clinical routine – 24-months results from the prospective non-interventional FINESSE study
Abstract Background The CGRP pathway targeting antibody fremanezumab is indicated for prevention of migraine in adults with ≥4 migraine days/month. To address the limited availability in real-world long-term data, the FINESSE study was initiated to provide real-world evidence of long-term effectiven...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-12-01
|
| Col·lecció: | The Journal of Headache and Pain |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s10194-025-02259-x |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|